NC100150

 

Topic mentions per year

Topic mentions per year

1999-2015
051019992015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
The aim of this study was to test the safety and efficacy of NC100150 injection for steady-state contrast-enhanced peripheral MR… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2002
2002
PURPOSE To determine the diagnostic value of a new ultrasmall superparamagnetic iron oxide Clariscan, (NC100150) for the… (More)
Is this relevant?
2001
2001
A superparamagnetic nanoparticle (NC100150 Injection) was investigated in two different animal models; renal perfusion in pigs… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2001
2001
The authors evaluated the feasibility of combining single-shot T2-weighted turbo spin-echo magnetic resonance (MR) imaging and… (More)
Is this relevant?
2000
2000
A preparation of monocrystalline iron oxide nanoparticles with an oxidized starch coating, currently in clinical trials (NC100150… (More)
Is this relevant?
2000
2000
The influence of increasing doses of NC100150 Injection (Clariscantrade mark) and echo times on visualization of pulmonary… (More)
Is this relevant?
1999
1999
In this Phase I clinical study, a novel ultrasmall superparamagnetic iron oxide contrast agent, NC100150 Injection (Nycomed… (More)
Is this relevant?
1999
1999
A new ultrasmall superparamagnetic iron oxide (Clariscan; NC100150 Injection) was studied in domestic farm pigs. The T1 effects… (More)
Is this relevant?
1999
1999
This is the first study of the intravascular iron oxide particle contrast agent, NC100150 Injection (Nycomed Imaging AS, Oslo… (More)
  • table I
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1999
1999
In this phase I clinical study, the new ultrasmall superparamagnetic iron oxide contrast agent, NC100150 Injection (Nycomed AS… (More)
Is this relevant?